In 290 Chinese patients with advanced squamous NSCLC after platinum chemotherapy, sintilimab vs docetaxel improved median OS (11.79 vs 8.25 months; HR 0.74; 280 analysed) and PFS, with fewer grade ≥3 treatment-related adverse events (18.1% vs 36.2%).
RCTn = 290
Shi et al. Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3)